Recombinant DLL3 (Rovalpituzumab Biosimilar) antibody (PE)

Catalog No. ABIN7829112

The PE-conjugated Humanized Monoclonal anti-DLL3 (Rovalpituzumab Biosimilar) antibody (ABIN7829112) specifically detects DLL3 (Rovalpituzumab Biosimilar) in FACS. The antibody is reactive with Human samples.

Quick Overview for Recombinant DLL3 (Rovalpituzumab Biosimilar) antibody (PE) (ABIN7829112)

Target: DLL3 (Rovalpituzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This DLL3 (Rovalpituzumab Biosimilar) antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Grade: Research Grade

Product Details anti-DLL3 (Rovalpituzumab Biosimilar) Antibody (PE)

Purpose: PE-conjugated Anti-DLL3(Rovalpituzumab biosimilar) mAb

Isotype: IgG1, kappa

Application Details

Application Notes: Flow Cyt 1:400

Comment:

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Liquid PBS with 0.05 %  Proclin300, 1 % BSA

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2°C-8°C for 6 months

Expiry Date: 6 months

Target Details for DLL3 (Rovalpituzumab Biosimilar)

Target: DLL3 (Rovalpituzumab Biosimilar)

Alternative Name: Rovalpituzumab Biosimilar

Target Type: Biosimilar

Background: Synonyms Target:SCDO1
Synonyms Antibody:SC0001-SCX,SC0002,sc0001-SCX

UniProt: Q9NYJ7